Communicable Diseases
Surveillance Bulletin
November 2004
A bimonthly publication of the National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS)

CONTENTS

Epidemic prone disease surveillance table.......................................................... 2
WHO influenza virus vaccines composition recommendation............................ 3
The HIV & AIDS management, treatment & support programme....................... 3
Cholera................................................................................................................. 5
Eliminating measles, South Africa, 2004............................................................. 5

Before and after treatment for HIV/AIDS/TB co-infection, March and September 2003. (David Walton/PIH)

This bulletin is available on the NICD website: http://www.nicd.ac.za
Requests for e-mail subscription are invited - please send request to Mrs Liz Millington: lizm@nicd.ac.za
Material from this publication may be freely reproduced provided due acknowledgement is given to the author, the Bulletin and the NICD
<table>
<thead>
<tr>
<th>Disease / Organism</th>
<th>Age Group</th>
<th>Serotype</th>
<th>Resistance</th>
<th>2003</th>
<th>2004</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measles IgM positive results</td>
<td>All ages</td>
<td></td>
<td></td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Rubella IgM positive results from measles IgM negative patients</td>
<td>All ages</td>
<td></td>
<td></td>
<td>115</td>
<td>87</td>
</tr>
<tr>
<td>CCHF</td>
<td>All ages</td>
<td></td>
<td></td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rabies, human</td>
<td>All ages</td>
<td></td>
<td></td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Haemophilus influenzae</td>
<td>Non-serotype b</td>
<td></td>
<td></td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Non-typable</td>
<td></td>
<td></td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Unknown serotype</td>
<td></td>
<td></td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Meningococcal disease</td>
<td>All ages</td>
<td></td>
<td></td>
<td>14 18 114 21</td>
<td>23 33 176 71</td>
</tr>
<tr>
<td></td>
<td>Age &lt; 5 years</td>
<td></td>
<td></td>
<td>32 40 479 73</td>
<td>53 49 496 40</td>
</tr>
<tr>
<td>Streptococcus pneumoniae, invasive</td>
<td>Penicillin, non-susceptible, all ages</td>
<td></td>
<td></td>
<td>12 368 49 1</td>
<td>12 368 49 1</td>
</tr>
<tr>
<td></td>
<td>Susceptibility unknown, all ages</td>
<td></td>
<td></td>
<td>9 17 105 10</td>
<td>9 17 105 10</td>
</tr>
<tr>
<td>Salmonella species - invasive isolates</td>
<td>All ages</td>
<td></td>
<td></td>
<td>53 99 19 19</td>
<td>78 99 19 19</td>
</tr>
<tr>
<td></td>
<td>All serotypes excl. S typhi</td>
<td></td>
<td></td>
<td>9 17 105 10</td>
<td>7 22 50 46</td>
</tr>
<tr>
<td>Salmonella typhi</td>
<td>All ages</td>
<td></td>
<td></td>
<td>2 0 16 2</td>
<td>2 0 16 2</td>
</tr>
<tr>
<td>Shigella species</td>
<td>All ages</td>
<td></td>
<td></td>
<td>53 99 19 19</td>
<td>78 99 19 19</td>
</tr>
<tr>
<td></td>
<td>All serotypes excl. S typhi</td>
<td></td>
<td></td>
<td>9 17 105 10</td>
<td>7 22 50 46</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>All ages</td>
<td></td>
<td></td>
<td>12 368 49 1</td>
<td>12 368 49 1</td>
</tr>
<tr>
<td></td>
<td>VBL cholerae 01</td>
<td></td>
<td></td>
<td>53 99 19 19</td>
<td>78 99 19 19</td>
</tr>
</tbody>
</table>

Note: The above are NICD laboratory data and do not necessarily reflect a quantitative measure of disease in the country.
During the period February to September 2004, influenza A(H1N1 and H1N2), A(H3N2) and B viruses circulated in many parts of the world.

Influenza A(H1N1 and H1N2) viruses were isolated from sporadic cases in many countries, while two countries reported outbreaks. Most isolates were antigenically similar to A/New Caledonia/20/99. Current vaccines containing A/New Caledonia/20/99 antigen stimulated HA antibodies against recent A(H1) influenza isolates, which were of similar titre and frequency to those against the vaccine virus.

Influenza A(H3N2) viruses were associated with outbreaks in many countries. While the majority of isolates were similar to A/Fujian/411/2002, an increasing proportion of recent isolates was distinguishable from the A/Wyoming/3/2003 vaccine virus and more closely related to A/Wellington/1/2004. Current vaccines containing A/Wyoming/3/2003 antigen stimulated HA antibodies that were lower in frequency and titre to A/Wellington/1/2004-like viruses than to the vaccine virus.

Influenza B activity occurred sporadically with only one reported outbreak. The majority of recent isolates were antigenically similar to B/Shanghai/361/2002. Current vaccines containing influenza B/Shanghai/361/2002-like antigen stimulated HA antibodies to recent B/Shanghai/361/2002-like isolates that were of similar titre and frequency to those against the vaccine virus.

The influenza season in South Africa was mild, with viruses isolated from early May to August. All the isolates except one were influenza A(H3N2) and were closely related to the A/Wellington/1/2004 strain. The remaining isolate was influenza B and shared close similarity to strains isolated in Israel and Madagascar.

As in previous years, the national control authorities should approve the specific vaccine viruses used in each country. National public health authorities are responsible for recommendations regarding the use of the vaccine. WHO has published recommendations on the prevention of influenza.

Most of the population is likely to have been previously infected with influenza A(H1N1 and H1N2), influenza A(H3N2) and influenza B viruses. As a consequence, 1 dose of inactivated influenza vaccine should be immunogenic for individuals of all ages except young children. Previously unimmunised children should receive 2 doses of inactivated vaccine with an interval between doses of at least 4 weeks.

Updated epidemiological information is available on WHO’s web site at http://www.who.int/influenza.

It is recommended that vaccines to be used in the 2005 season (southern hemisphere winter) contain the following:
]
— an A/New Caledonia/20/99(H1N1)-like virus;
— an A/Wellington/1/2004(H3N2)-like virus;
— a B/Shanghai/361/2002-like virus.*

*Currently used vaccine viruses include B/Shanghai/361/2002, B/Jilin/20/2003 and B/Jiangsu/10/2003

Reference
diagnostic material. From 1 April 2004 the first clinical sites were ready to implement the programme. A target was set of starting 53 000 people on anti-retroviral treatment by the end of March 2005. One hundred and thirteen clinic sites would carry out the administration of this treatment across South Africa. This would increase each year until, by five years into the programme, treatment would be available to 100% of the population that needed it.

From inception of the programme, the National and Provincial Departments of Health have been collecting data on the numbers of people screened and placed on treatment, adverse events occurring due to drug toxicity, the pharmaceutical system, the nutritional support programme, and the laboratory monitoring. Plans for the development of a National Patient Master Index and Patient Information System have been accelerated in support of the programme. Until this is fully implemented, data is collected locally either on existing IT networks, or manually on a paper-based system, transferred across to district level, and thence to National and Provincial Health Departments.

In compliance with the plan, all people testing positive for HIV are screened clinically and with CD4 testing. When the CD4 count drops to 200 cells/mm$^3$, or the person develops WHO stage IV disease irrespective of CD4 count, antiretroviral therapy is commenced. Baseline viral load is measured and then repeated at 6 month intervals together with follow up CD4 testing. Improving CD4 counts and decreasing viral load to undetectable levels indicate a good response to therapy. Treatment failure would be suspected if viral load rebounded. This could be due to failed compliance with the recommended regimen, the development of viral resistance to the drugs, or discontinuation of treatment due to toxic side effects.

Within the NHLS, the decision was made to use the PLG CD4 method for CD4 counting. This enabled us to decrease the costs of CD4 tests by 50%. In addition, this method displays excellent reproducibility within and between laboratories. The BioMeriuex EasyQ viral load system was selected as the system for monitoring patients on antiretroviral therapy. A new automated extraction system has now completed validation and will be ready for use from early 2005. The combination of this automated extraction system with the real-time amplification and detection assay should permit rapid turn around times, and high throughput of specimens each day, while minimizing user error and contamination risks.

Six months into the programme, NHLS had already tested in excess of 130 000 patient samples for CD4 counts. Approximately 50% of these samples demonstrated CD4 counts of below 200 cells/mm$^3$, and 20% overall had CD4 counts below 50 cells/mm$^3$. In the same period, 16 000 viral load tests were completed with more than 50% measuring more than 50 000 copies/ml. These statistics stress the urgency of this programme, highlighting the need to accelerate the availability of drugs to the population accessing the clinical services.

HIV contributes in no small way to increasing the effects of poverty on the continent of Africa. The nature of the transmission of this infection determines that it is predominantly the younger, more sexually active sector of the population that is targeted by the disease. These are the parents, the labour force, the professionals, the agricultural producers, and the people who have traditionally supported the needs of the generations that come before and after them. Needless to say, the impact is felt across all age groups, as even those not infected by this virus feel the effects of it. Apart from the increasing burden placed on the health care services, proper management of HIV and AIDS is a financial imperative, particularly as the costs associated with the treatment and monitoring of the disease become increasingly affordable.

While no public health programme on as ambitious a scale as this will ever go perfectly according to plan, much has been achieved through the planning and early implementation phases of the programme, ensuring ever increasing access to this life saving intervention. Criticism will no doubt be levelled at the National Department of Health for all sorts of reasons, some valid and some less so. It is time, however, to practice a measure of advocacy in support of all the work and good that has been achieved. This is more likely to ensure the ongoing commitment of, and assist in maintaining the impetus already gained by the political system of this country than whittling away at the credibility of people who have made considerable personal effort to overcome the inertia of the past. If the fear of criticism is lessened, the doors of communication will be more likely to be opened, and greater transparency of all processes will result. This could result in a self perpetuating cycle of confidence building that can only be of benefit to health care and political credibility in this country overall.
ELIMINATING MEASLES, SOUTH AFRICA, 2004
Bernice N Harris, Jo McAnerney, Lucille Blumberg, Sheilagh Smit, Epidemiology Unit, NICD

INTRODUCTION

Measles is caused by a virus of the genus Morbillivirus in the Paramyxoviridae family. Eight different strains of measles viruses (23 genotypes) have been identified to date; some of these circulate endemically in certain countries. Measles virus is transmitted by infected droplets during coughing, sneezing, through direct contact with nasal or throat secretions of infected persons or by touching contaminated objects. It is predominantly a childhood disease causing rash, fever and any of the following: cough, coryza and conjunctivitis. Vaccination changes the age distribution of measles cases, depending on the coverage and targeted age groups. It is highly infectious and spreads rapidly amongst people who are not immune, leading to significant morbidity and mortality as a result of prolonged induced immune suppression.

The most common complications are pneumonia, either due to the measles virus or as a result of secondary bacterial or viral infection, diarrhea, croup, otitis media, mouth ulcers and eye pathology. Less commonly, encephalitis may complicate measles in 1 in 1000 reported cases resulting in permanent brain damage. Myocarditis, pneumothorax, pneumomedia-stinum, appendicitis and sub-acute sclerosing panencephalitis (SSPE), a fatal chronic infection of the brain have all been reported.

DISEASE BURDEN

In spite of available vaccination, measles remains a heavy public health burden worldwide especially in developing countries with 30-40 million cases, 26 million disability adjusted life years (DALYs) and 745 000 deaths for the year 2001. This represents 50-60% of the estimated million deaths attributable to vaccine-preventable diseases of childhood. Measles may be ultimately responsible for more child deaths than any other single agent because of complications from pneumonia, diarrhea and malnutrition. Measles is also the major cause of preventable blindness in the world, affecting the same disadvantaged populations.

Of the deaths attributable to measles, 98% occur in developing countries, where vitamin A deficiency is common. Case-fatality rates in these countries are usually estimated to be in the range 1-5% but may reach 10-30% in some situations.
ACCELERATED CONTROL, ELIMINATION AND ERADICATION

Measles, like polio and smallpox, can potentially be eradicated as it infects only humans, no carrier state or environmental reservoir exists and an effective vaccine is available.

Measles elimination refers to interruption of transmission in a sizable geographic area in which vaccination would nevertheless need to continue because of the continued threat of reintroduction of the virus. Eradication, defined as the global interruption of measles transmission, represents the sum of successful elimination efforts in all countries. Once eradication is achieved, vaccination could be stopped without risk for measles outbreaks.

Successes in interrupting indigenous transmission of measles virus in the Americas and in the United Kingdom prompted the World Health Organization (WHO), Pan American Health Organization (PAHO), and CDC to convene a meeting in July, 1996 to consider the feasibility of global measles eradication. Presentations at the meeting included an overview of global measles control and elimination efforts; detailed reviews of successful measles elimination efforts in Latin America, the English-speaking Caribbean, Canada, and the United States; surveillance for clinical disease; laboratory tools for antibody detection and virus identification; and other factors that might influence the feasibility of disease eradication.

The meeting concluded that although measles eradication is a logical addition to and extension of the poliomyelitis eradication initiative, the effort should build on the success of poliomyelitis eradication. Consequently, measles eradication should not be undertaken immediately and simultaneously in all parts of the world. Measles eradication efforts should await maturation of the poliomyelitis eradication program in each region of the globe, and should be implemented as countries and regions become free of poliomyelitis. Because of the rapid accumulation of persons susceptible to measles, the implementation phase of an eradication effort should be compressed into as brief a time as possible. Research into the molecular pathogenesis of measles and the immune response to measles virus infection should continue.4

SA OUTBREAKS, 2004

From January to October 2004, 522 laboratory confirmed measles cases have been detected in South Africa, of which 488 (93.5%) occurred in Gauteng Province. Sporadic cases have occurred in all provinces except the Free State with localised limited outbreaks in KwaZulu-Natal, Mpumalanga, the Western and Northern Cape (figure 1).

Cases occurred during all epidemiological weeks except week 5 and 7. Cases increased in the winter weeks from week 25. The highest number of cases occurred in week 30.

The age distribution of cases has ranged from 1 month to 31 years with the median age of 10 months. However, the age distribution in the various outbreaks has reflected underlying contributing factors with mostly young adults affected in the Western Cape related to low immunisation coverage in migrant, mobile populations and mostly young infants in Gauteng probably due to accumulation of susceptibles, mobile populations and high population density.

10.4% of cases had no recorded age, most of whom were seen in hospital out patient departments. These patients were most likely not sick enough to be admitted and may differ in age distribution from the cases with known ages, demonstrating the importance of completing all fields of case investigation and laboratory request forms.

The national mass measles and polio vaccination campaign for children under 5 years of age took place in the last week of July (week 31). Although numbers did not decrease, the proportion of cases in the age group targeted by the campaign significantly decreased (figure 2 and figure 3).

Genotyping of the virus has shown that the same virus strain, probably introduced from a neighbouring country in mid 2003, has been responsible for all the measles cases.

STRATEGIES TO CONTAIN MEASLES OUTBREAKS

The national Expanded Programme on Immunisation (EPI-SA) has identified the following measures to interrupt transmission of indigenous measles in South Africa based on internationally agreed strategies. These measures are discussed in the document Strategies to contain measles outbreaks in South Africa, Department of Health, 2003.

Internationally recommended strategies to eliminate measles include:

- High routine coverage to ensure a high level of herd immunity
- Mass immunisation campaigns that provide a second opportunity for measles immunisation
- Mop up campaigns in areas of low coverage
- Case based surveillance for all suspected cases with laboratory confirmation

These strategies may be divided into three broad activities:

- Primary prevention
South Africa adopted the measles elimination strategy in 1997 and case based surveillance with laboratory confirmation of suspected measles cases was introduced in 1998. The National Department of Health pays for the testing of blood and urine specimens of all suspected measles cases tested at the NICD.

Due to the non specific clinical presentation and concurrent rubella outbreaks, it is essential that all suspected cases have a blood and urine specimen taken to confirm the diagnosis and guide intervention strategies.

Addressing nosocomial spread is critical in any measles outbreak and all admissions to institutions should be immunised from 6 months of age. This dose is additional to the routine 9 and 18 month doses and should be recorded on the road to health card in the space provided for other immunisations. Patients with rash and fever or suspected measles cases should be seen promptly and not wait in queues and crowded waiting areas, and isolated if admitted. Hospitals and institutions such as children’s homes must provide measles vaccination to all children and staff that have no evidence of previous vaccination.

CONCLUSION

It has been widely demonstrated that measles elimination is achievable. The last indigenous measles case in the Americas occurred on 20 September 2002. Transmission of indigenous measles has been mostly interrupted in Canada since 1998. Finland achieved elimination through high immunisation coverage in 12 years and Albania through high coverage and targeted mass campaigns in less than 3 years.

High routine immunisation coverage is a critical part of achieving and maintaining interruption of indigenous transmission and limiting outbreaks due to importation of measles virus. This can only be reached through optimising all opportunities to immunise children at any visit to a health facility, whether for growth monitoring or accompanying an adult for a blood pressure check-up.

References

4. CDC. Measles Eradication: Recommendations from a Meeting Cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. MMWR 1997:46(RR11);1-20.
Fig 1: Confirmed measles and rubella cases per province, South Africa, 2004

Fig 2: Confirmed measles cases per epidemiological week, South Africa, 2004

Fig 3: Age distribution of patients with measles before and after the mass immunisation campaign, South Africa, 2004

Jan-Aug N=325
Sep/Oct N=197

P = < 0.0001